This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
HIV/AIDS	HIV env; Fc γ -receptor (FCGR)	<p>Mouse studies suggest strengthening the affinity of broadly neutralizing antibodies (bNAbs) for activating FCGRs could enhance their therapeutic effect against HIV infection. In a humanized mouse model of HIV infection, chimeric human-mouse bNAbs that bound to activating FCGRs conferred better protection against infection than those that bound to inhibitory FCGRs. In a humanized mouse model of HIV infection, bNAbs with a human IgG1 Fc region engineered to have enhanced binding to activating FCGRs conferred increased protection against infection compared with those that had a wild-type Fc region. Next steps include testing the enhanced bNAbs in nonhuman primates.</p> <p><i>SciBX</i> 7(38); doi:10.1038/scibx.2014.1125 Published online Oct. 2, 2014</p>	Patent and licensing status undisclosed	<p>Boumazos, S. <i>et al. Cell</i>; published online Sept. 11, 2014; doi:10.1016/j.cell.2014.08.023 Contact: Jeffrey V. Ravetch, The Rockefeller University, New York, N.Y. e-mail: ravetch@rockefeller.edu</p>